Information Technology · Services-Computer Programming, Data Processing, Etc.

HCAT Health Catalyst, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1636422106 filings
Russell 2000

HCAT at a glance

Health Catalyst, Inc. (HCAT, SEC CIK 1636422) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Health Catalyst, Inc. (HCAT) reported revenue of $311.1 million (up 1.5% from FY2024) and a net loss of $178.0 million. Diluted EPS was -$2.55.
  • As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Health Catalyst, Inc. (HCAT) shares worth $11.5 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Landry Benjamin on November 12, 2026 of 29,478 shares at $1.39 per share.
  • In the last 90 days, HCAT insiders reported 1 open-market purchase ($105K) and 2 open-market sales ($141K) on Form 4, a net sale of $36K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$311.1M
+1.5% vs prior year
Insiders · 90 days
1 buy · 2 sells
Net −$36K
13F holders
23 funds
$11.5M · +0 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $56.3M, down 26% YoY from $76.3M, driven by Vitalware divestiture and DOS-to-Ignite churn
  • Total gross margin 31% vs 39% YoY; net income $40.5M vs $22.2M loss, including $65.9M Vitalware gain
  • Technology revenue $40.7M, down 22%; professional services $15.6M, down 36%, the weaker segment
  • Cash from operations $16.9M vs $9.2M used YoY; $144.5M Vitalware proceeds funded debt repayment
  • Near-term headwinds: Medicaid cuts, elongated sales cycles, Ignite migration churn, and lower technology margins through 2027

Risk Factors

  • Newly added regulatory risk: OBBBA Medicaid funding reductions enacted July 2025 could reduce enrollment and covered services
  • Most material update: Project Nexus reduced global workforce approximately 7% by second quarter 2026, risking execution and employee attrition
  • AI compliance risk: California, Colorado, Texas, and Utah enacted or advanced requirements affecting AI safeguards, disclosures, and accountability
  • Near-term operating risk: DOS-to-Ignite migration continues causing client churn, downselling, and smaller bookings
  • Financial concentration risk: Three largest clients represented 13.6% of 2025 revenue, increasing exposure to renegotiations or loss of major accounts

AI summary of the HCAT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 fiscal 2026 results released for quarter ended September 30, 2026
  • Exhibit 99.1 contains Health Catalyst’s financial results and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 revenue $56.3M, down 26% YoY after Vitalware divestiture and DOS-to-Ignite migration headwinds
  • Adjusted EBITDA $0.8M, down 94% YoY, signaling sharply weaker underlying profitability despite cost reductions
Filed Sep 14, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Tami Reller joins HCAT’s Board October 1, expanding director count from six to seven
  • Reller becomes Audit Committee chair, replacing Justin Spencer, who remains on the committee

Item EX-99.1: Item EX-99.1

  • Tami Reller appointed director effective October 1, 2026, adding healthcare, technology, finance, and public-company governance expertise
  • Reller becomes audit chair and joins compensation committee, strengthening oversight during Health Catalyst’s leadership transition

Item 7.01: Regulation FD Disclosure

  • Health Catalyst appointed Ms. Reller to its Board on September 14, 2026
  • Board addition may influence governance, strategic oversight and shareholder confidence
Filed Sep 8, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Simeon Kohl becomes CEO, President and director September 14, 2026, replacing Ben Albert
  • Kohl brings prior CEO experience at Performant Healthcare and healthcare technology leadership

Item EX-99.1: Item EX-99.1

  • Simeon Kohl becomes CEO, President, and director effective September 14, 2026
  • Ben Albert transitions to Chief Business Officer and leaves the Board effective September 13, 2026

Item 7.01: Regulation FD Disclosure

  • Exhibit 99.1 announces officer and director transitions at Health Catalyst
  • Board plans RSU grants for Mr. Kohl tied to his appointments

AI summaries of HCAT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for HCAT

Don't miss the next HCAT filing

  • Alerts as it files. A push when HCAT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut HCAT, by share count.
  • Ask anything. An AI agent that reads every HCAT filing and answers with sources.

HCAT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Landry BenjaminSellNov 12, 2026$1.39
Landry BenjaminSellNov 11, 2026$1.43
Reller TamiAOct 1, 2026-
Kohl SimeonASep 14, 2026-
Kohl SimeonBuySep 14, 2026$1.79
Albert BenjaminFSep 10, 2026$1.67
Alger JasonFSep 1, 2026$1.70
Larson-Green JulieASep 1, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$306.6M$311.1M
Operating Income--$69.8M-$160.9M
Net Income-$118.1M-$69.5M-$178.0M
Op. Margin--22.8%-51.7%
Net Margin--22.7%-57.2%
Balance Sheet
Total Assets-$858.9M$502.6M
Equity$366.9M$365.2M$245.8M
ROE-32.2%-19.0%-72.4%
Per Share
EPS$-2.09$-1.15$-2.55
Cash Flow
Operating CF-$14.6M$731K
CapEx$1.2M$1.6M$968K

Source: XBRL data in Health Catalyst, Inc. (HCAT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate HCAT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
HCAT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202623$11.5M
Q2 202623$18.6M
Q1 202621$18.4M
Q4 202522$40.6M
Q3 202524$53.7M
Q2 202525$62.2M
Q1 202523$52.3M
Q4 202420$91.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 181 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

HCAT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 13, 2026--
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
4Oct 5, 2026--
4Sep 16, 2026--
8-KSep 14, 2026Analysis-
4Sep 11, 2026--
8-KSep 8, 2026Analysis-
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
SC 13GJul 21, 2026-
4Jul 20, 2026--
4Jul 20, 2026--
4Jul 20, 2026--
4Jul 20, 2026--
8-KJul 20, 2026Analysis-
SC 13DJun 22, 2026-
4Jun 15, 2026--
8-KJun 4, 2026Analysis
4Jun 3, 2026-
4Jun 3, 2026-

Related Information Technology companies

All Information Technology →

HCAT SEC filings: frequently asked questions

Are HCAT insiders buying or selling?

In the last 90 days, Health Catalyst, Inc. (HCAT) officers, directors and 10% owners reported 1 open-market purchase worth $105,439 by 1 insider and 2 open-market sales worth $140,974 by 1 insider on Form 4, a net sale of $35,535. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold HCAT stock?

As of September 30, 2026, the largest Health Catalyst, Inc. (HCAT) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($4.8 million), BlackRock ($2.7 million), State Street Corp ($603,000), Millennium Management ($462,000), Goldman Sachs Group ($397,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was HCAT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Health Catalyst, Inc. (HCAT) reported revenue of $311.1 million (up 1.5% from FY2024) and a net loss of $178.0 million. Diluted EPS was -$2.55. The figures come from the XBRL data in the 10-K.

What did HCAT report in its latest 8-K?

Health Catalyst, Inc. (HCAT) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 fiscal 2026 results released for quarter ended September 30, 2026.

What are the latest HCAT SEC filings?

Health Catalyst, Inc. (HCAT) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 13, 2026.

What is HCAT's SEC CIK number?

Health Catalyst, Inc. (HCAT)'s SEC Central Index Key (CIK) is 1636422. EDGAR lists every HCAT filing under that number.

Ask anything about HCAT

The research agent reads HCAT's filings, financials, insider trades and 13F holders, then answers with sources.